Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bicycle Therapeutics Plc ADR (BCYC)

Bicycle Therapeutics Plc ADR (BCYC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,014,286
  • Shares Outstanding, K 69,046
  • Annual Sales, $ 26,980 K
  • Annual Income, $ -180,660 K
  • EBIT $ -196 M
  • EBITDA $ -190 M
  • 60-Month Beta 0.86
  • Price/Sales 37.22
  • Price/Cash Flow N/A
  • Price/Book 1.21

Options Overview Details

View History
  • Implied Volatility 100.63% ( +49.08%)
  • Historical Volatility 115.62%
  • IV Percentile 74%
  • IV Rank 54.64%
  • IV High 148.37% on 11/26/24
  • IV Low 43.12% on 06/03/24
  • Put/Call Vol Ratio 0.07
  • Today's Volume 44
  • Volume Avg (30-Day) 175
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 1,389
  • Open Int (30-Day) 8,000

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.86
  • Number of Estimates 7
  • High Estimate -0.68
  • Low Estimate -1.01
  • Prior Year -1.16
  • Growth Rate Est. (year over year) +25.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.17 +19.97%
on 12/13/24
21.50 -32.10%
on 12/10/24
-5.80 (-28.43%)
since 11/26/24
3-Month
12.17 +19.97%
on 12/13/24
28.67 -49.08%
on 10/16/24
-8.72 (-37.39%)
since 09/26/24
52-Week
12.17 +19.97%
on 12/13/24
28.67 -49.08%
on 10/16/24
-4.01 (-21.55%)
since 12/26/23

Most Recent Stories

More News
Why Shares of Bicycle Therapeutics Were Rising on Monday

The company said it is working with the FDA to structure a phase 2/3 trial for its bladder cancer therapy.

NVS : 98.40 (+0.05%)
BCYC : 14.60 (-0.61%)
Why Bicycle Therapeutics Stock Raced Ahead Today

The company's latest attempt at capital raising seems to be having enviable success.

GS : 581.23 (-0.27%)
JEF : 79.80 (+1.54%)
BCYC : 14.60 (-0.61%)
Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 14.60 (-0.61%)
Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced...

BCYC : 14.60 (-0.61%)
Bicycle Therapeutics to Present at the 2023 AACR Annual Meeting

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today...

BCYC : 14.60 (-0.61%)
Bicycle Therapeutics Enhances Leadership Team with Key Appointments

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 14.60 (-0.61%)
Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 14.60 (-0.61%)
Bicycle Therapeutics to Participate in Upcoming Investor Conferences

Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 14.60 (-0.61%)
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today reported...

BCYC : 14.60 (-0.61%)
Bicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced...

BCYC : 14.60 (-0.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 15.49
2nd Resistance Point 15.29
1st Resistance Point 14.95
Last Price 14.60
1st Support Level 14.41
2nd Support Level 14.21
3rd Support Level 13.87

See More

52-Week High 28.67
Fibonacci 61.8% 22.37
Fibonacci 50% 20.42
Fibonacci 38.2% 18.47
Last Price 14.60
52-Week Low 12.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar